(资料图)

The city of Taizhou in east China’s Jiangsu province has made every effort to rev up the development of big health industry.

Leiling Bai’ao Biotechnology is a fully enclosed intelligent molecular diagnostic system developer dedicated to solving the pain points of precise diagnosis and non-toxic treatment in the animal husbandry and veterinary industry. The enterprise has gained more and more confidence with the inclusion of China Pharmaceutical City in the pilot development zone of the national new vaccine and specific diagnostic reagent industry cluster.

“Our veterinary molecular diagnostic technology is developing towards precision and high intelligenceand will be promoted nationwide and even globally in the future” Dr. Chen Lei, Chairman of Taizhou Leiling Bai’ao Biotechnology Co., Ltd., said.

Compared to ordinary industries, the pharmaceutical industry is characterised by high technology, high investment,andhigh output, but long research and development cycles, and therefore relatively slow returns. To this end, Taizhou has identified its positioning and strengthened its cluster advantages for both development and risk prevention, ensuring that it increases investment while also meeting its actual capabilities.

“In recent years,we have targeted international cutting-edge technologies,focusing on the development of new biopharmaceuticaland chemical formulations in vitro diagnostic reagentsand high-end medical devices as pillar industriesand enhanced the development of special medicalformula foods and animal health drugs as specialty industries”, Zhao Ronglin, Deputy Director of the Taizhou Pharmaceutical Park Administration, said.

Taizhou Pharmaceutical Park has also made every effort to introduce high growth enterprises with high correlation, wide radiation, strong driving force, and sufficient innovation motivation, forming a complete industrial chain of research and development, manufacturing, and sales.

Jiang Zhijun, founder of Changtai Pharmaceutical, said that the company’s development of high-end innovative formulation technology of microspheres and liposomes can participate in global competition and share in the billions of yuan market. The high-quality service of the pharmaceutical park has ensured that the company can focus on scientific research without any distractions.

“When we settled in the pharmaceutical parkwith the support of the park administration,we completed the registration in just one weekand factory design and construction bidding in less than two months.In the process of applying for GMPcertified new drug registration,the park administration provided advanced services” Jiang Zhijun,the founder of Jiangsu Changtai Pharmaceutical, said.

Centering around registration and settlement, technology incubation, new drug application, and financial support, Taizhou Pharmaceutical Park has built a total of 21 public technology service platforms, enabling the city’s pharmaceutical industry to rank first in prefecture-level cities nationwide, account for one-fifth of the provincial total and one-twentieth of the national total. In the meantime, the city’s biomedical cluster ranked among the third round of national advanced manufacturing clusters.